Faron, etusivu

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | May 05, 2026 at 10:30:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 30/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 04/05/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 9.55% 15.44% 24.99% 50,753,166
Position of previous notification (if
applicable)		 10.00% 15.44% 25.44%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 19,393,166 31,360,000 9.55% 15.44%
SUBTOTAL 8. A 50,753,166 24.99%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 9.55% 15.44% 24.99%
CVI Investments, Inc. 9.55% 15.44% 24.99%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 04.05.2026

Faron Pharmaceuticals Ltd: Directorate Appointment

Faron Pharmaceuticals Ltd | Company announcement | May 05, 2026 at 09:00:00 EEST

Faron Pharmaceuticals Ltd: Directorate Appointment

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (“Faron”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, is pleased to announce the appointment of Dr. George Stanley Golumbeski as a Non-executive Director of the Company with immediate effect.

Dr. Golumbeski currently focuses on supporting the growth of emerging companies as a partner at DROIA Ventures, a specialized biotech investment firm. He previously spent nearly ten years as Executive Vice President of Business Development at Celgene, where he led partnerships with biotechnology companies aimed at delivering innovative treatments for cancer and chronic inflammatory diseases. Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing and Strategy at Novartis. Prior to Novartis, he was Vice President of R&D Business Development at Elan and Vice President of Corporate Development at Schwarz Pharma, where he led CNS acquisitions worldwide. Dr. Golumbeski earned a Ph.D. in Genetics from the University of Wisconsin–Madison, completed postdoctoral research in molecular biology at the University of Colorado Boulder, and received a B.A. in Biology from the University of Virginia.

The following information regarding the appointment of Dr. Golumbeski is disclosed under Schedule 2(g) of the AIM Rules for Companies and Nasdaq First North Growth Market Rulebook.

Current positions, directorships and/or partnerships: Former positions, directorships and/or partnerships (within the last five years):
Actio Biosciences, Inc Acceleron Pharma, Inc
Acumen Pharmaceuticals, Inc Ananke Therapeutics, Inc
Droia Ventures Vicinitas Therapeutics, Inc
Judo Bio, Inc Chroma Medicine, Inc
National Audubon Society, Inc GRAIL, Inc
Peptone Ltd MorphoSys US, Inc
Shattuck Labs, Inc Mural Oncology PLC
Carrick Therapeutics Limited Mural Oncology, Inc
Sage Therapeutics, Inc
Tizona Therapeutics, Inc

Dr. Golumbeski holds no ordinary shares or options or warrants over ordinary shares in the Company.

Save as set out above, no further information regarding Dr. Golumbeski is required to be disclosed pursuant to the AIM Rules for Companies or Nasdaq First North Growth Market Rulebook.

Tuomo Patsi, Non-Executive Chairman of the Board of Faron Pharmaceuticals, said: “We are excited to welcome George to our board. His broad experience will be extremely valuable to Faron as we  continue to progress bexamarilimab towards next milestones and further develop our long term startegy as a company.”

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 

+1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner

+44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä

+358 (0)40 555 4727
+358 (0)50 553 8990

About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company’s pipeline is built on its scientific understanding of the regulation of the immune system in cancer.

About Bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

Faron Pharmaceuticals Ltd: Results of the Annual General Meeting

Faron Pharmaceuticals Ltd | Company announcement | May 04, 2026 at 14:00:00 EEST

Faron Pharmaceuticals Ltd: Results of the Annual General Meeting

TURKU, FINLAND – The annual general meeting (“AGM”) of Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) took place in Turku, Finland, today 4 May 2026. Thirty-nine shareholders representing 46,850,172 shares and votes were represented in the meeting. The AGM approved all the proposals of the Board of Directors (“Board”) and the Shareholder’s Nomination Board, set out in the notice of the AGM published on 10 April 2026.

Decisions of the AGM

The AGM adopted the financial statements of the Company and resolved to discharge the members of the Board and the CEO of the Company from liability for the financial year 2025.

No dividend for the financial year 2025 will be paid, and the losses of the Company for the financial year, amounting to EUR 27.2 million (IFRS), will be carried forward to the reserve for invested unrestricted equity.

Composition and remuneration of the Board

The number of members of the Board was confirmed as six. Tuomo Pätsi, Marie-Louise Fjällskog, Christine Roth, Colin Bond and Juho Jalkanen were re-elected, and George Golumbeski was elected as a new member to the Board for a term that ends at the end of the next AGM.

The AGM resolved that the annual remuneration of the members of the Board remain unchanged and that EUR 35,000 will be paid to the Board members, in addition to which an annual remuneration of EUR 35,000 will be paid to the chair of the Board. In addition, a further annual remuneration of EUR 11,000 will be paid to the chair of the audit committee, a further annual remuneration of EUR 9,000 will be paid to the chair of the remuneration committee and a further annual remuneration of EUR 6,000 will be paid to the chair of the nomination committee. In addition, a further annual remuneration of EUR 6,000 will be paid to the audit committee members, a further annual remuneration of EUR 5,000 will be paid to the remuneration committee members and a further annual remuneration of EUR 3,000 will be paid to the nomination committee members.

Meeting fees will be paid to the Board members as follows:

  • a meeting fee of EUR 1,000 will be paid to Board members per Board meeting where the Board member was physically present, and which was held on another continent than the member’s place of residence; and
  • no meeting fees will be paid to Board members who were attending a Board meeting but not physically present or for Board meetings held on the same continent than the member’s place of residence.

In addition, all reasonable and properly documented expenses incurred in the performance of duties of the members of the Board would be compensated.

No remuneration will be paid based on the Board membership of the CEO of the Company or a person serving the Company under a full-time employment or service agreement.

Auditor

Audit firm PricewaterhouseCoopers Oy (“PwC”) was re-elected as the Company’s auditor. PwC has appointed Panu Vänskä, authorized public accountant (KHT), as the key audit partner. It was decided that the auditor be remunerated in accordance with the invoice approved.

Authorization to the Board to decide on the issuance of shares, options or other special rights entitling to shares

The Board was authorized to resolve by one or more decisions on issuances of shares, option rights or other special rights entitling to shares as referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, which authorisation contains the right to issue new shares or dispose of the Company’s treasury shares held by the Company. The authorisation consists of up to forty million (40,000,000) new shares in the aggregate (including shares to be received based on option rights or other special rights), which corresponds to approximately twenty-five (25) per cent of the existing shares and votes in the Company (as of the date of this notice) and approximately twenty (20) per cent of the existing shares and votes in the Company after the completion of the rights offering in which a total of eighty million (80,000,000) new shares will be issued, as well as the conveyance of up to the same maximum number (80,000,000) of treasury shares held by the Company. Further, should the Board resolve to issue option rights or other special rights entitling to treasury shares held by the Company, the same authorisation could be used to issue the afore-mentioned up to forty million (40,000,000) new shares in the aggregate to the Company itself without consideration (to be further issued as shares from treasury or as shares to be received based on such option rights or other special rights). The authorisation will not exclude the Board’s right to decide on the issuance of shares, option rights or other special rights entitling to shares in deviation from the shareholders’ pre-emptive rights.

The Board was authorised to resolve on all other terms and conditions of the issuance of shares, option rights or other special rights entitling to shares.

The authorisation will be valid until 30 June 2027 and will not revoke the authorisations granted to the Board by the Extraordinary General Meeting on 2 March 2026 or the Annual General Meeting on 21 March 2025 to resolve on issuances of shares, option rights or other special rights entitling to shares.

Establishment of a new stock option 2026 plan

The AGM resolved to issue stock options to the personnel of the Company and its subsidiaries and to the members of the Board of Directors of the Company in accordance with the terms and conditions of the stock options 2026 (“Terms”), free of charge. In addition, the AGM authorised the Board to resolve on the implementation and administration of the stock options 2026, including the authority to interpret the Terms, adopt country-specific appendices, resolve on the allocation of stock options to personnel, and make any technical changes to the Terms as considered necessary. The maximum total number of stock options to be issued is 9,000,000, entitling their holders to subscribe for a maximum of 9,000,000 new shares in the Company or shares held by the Company.

Minutes of the AGM

The minutes of the AGM will be available on the Company’s website on 18 May 2026 at the latest.

For more information please contact:

Cairn Financial Advisers LLP, Nominated Advisor and Broker

Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990

About Faron Pharmaceuticals Oy 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.

Faron Pharmaceuticals Ltd: Issuance of warrants

Faron Pharmaceuticals Ltd | Company announcement | April 30, 2026 at 09:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary shares in the Company (“Warrants”), following the the amortisation of the first and second tranche convertible bonds to Heights Capital Management, Inc.at EUR 0.4516 announced on 13 April 2026.

The subscription price of all of the Warrants held by IPF is reset to EUR 0.4516 (“Subscription Price”). As described in the Warrant Terms and Conditions announcement of 8 April 2024, in the event of any future share issue at a price lower than the Subscription Price, the Subscription Price of the Warrants will be adjusted to that lower subsequent price.

Following this issues, IPF will have an interest in 3,641,467 Warrants, representing approximately 1.83% of the issued share capital in the Company. Each Warrant entitles its holder to subscribe for one new share in the Company. The Warrants may be exercised for a period of seven years from the original date of issue.

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen

 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company’s lead asset, bexmarilimab, is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at www.faron.com.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 22, 2026 at 14:30:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 17/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 20/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 10.00% 15.44% 25.44% 51,660,099
Position of previous notification (if
applicable)		 10.13% 15.44% 25.58%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
20,300,099 31,360,000 10.00% 15.44%
SUBTOTAL 8. A 51,660,099 25.44%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 10.00% 15.44% 25.44%
CVI Investments, Inc. 10.00% 15.44% 25.44%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 20.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 20, 2026 at 10:15:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 15/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 15/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 10.13% 15.44% 25.58% 51,929,014
Position of previous notification (if
applicable)		 8.37% 16.82% 25.19%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 20,569,014 31,360,000 10.13% 15.44%
SUBTOTAL 8. A 51,929,014 25.58%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 10.13% 15.44% 25.58%
CVI Investments, Inc. 10.13% 15.44% 25.58%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 15.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 20, 2026 at 10:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 14/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 14/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 8.37% 16.82% 25.19% 51,156,163
Position of previous notification (if
applicable)		 – 6.70% 6.70%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 16,996,163 34,160,000 8.37% 16.82%
SUBTOTAL 8. A 51,156,163 25.19%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 15,120,000 7.45%
Convertible Bond 12/02/2028 Anytime until maturity 19,040,000 9.38%
SUBTOTAL 8. B 1 34,160,000 16.82%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 8.37% 16.82% 25.19%
CVI Investments, Inc. 8.37% 16.82% 25.19%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 14.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 16, 2026 at 18:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights x
Other (please specify) iii: Dividend payments in kind.
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 15.4.2026
6. Date on which issuer notified (DD/MM/YYYY): 16.4.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 7.77% 15.509.433
Position of previous notification (if
applicable)		 12.69% 14.697.112
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 5.949.320 9.560.113 2.98% 4.79%
SUBTOTAL 8. A 15.509.433

7.77%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 2.98% 2.98%
Acme Investments SPF Sarl (Indirect) 4.79% 4.79%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron share issue during April 2026
Place of completion Monaco
Date of completion 16.4.2026

Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS

Faron Pharmaceuticals Ltd | Press Release | April 16, 2026 at 09:00:00 EEST

Strategic collaboration with a leading global CRO supports disciplined trial execution and operational efficiency, advancing Faron’s mission to provide treatment for patients with HR-MDS

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (“Faron”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, today announces that it has entered into an agreement with Parexel International (IRL) Limited, a leading global clinical research organization (CRO), to support the upcoming randomized Phase IIb BEXERA trial in treatment-naïve patients with higher-risk myelodysplastic syndromes (HR-MDS).

Parexel was selected based on its extensive global expertise in hematology and its proven track record in supporting complex, multinational clinical programs. The collaboration is focused on ensuring disciplined trial execution, with close alignment between the teams to support timely delivery and operational efficiency as the program progresses.

The BEXERA trial (FP2CLI012) is a randomized, double-blind, placebo-controlled Phase IIb trial in treatment-naïve HR-MDS. Planned to start in the second half of 2026, the trial will evaluate bexmarilimab at doses of 1 mg/kg and 3 mg/kg in combination with azacitidine, compared with placebo plus azacitidine.

The trial is expected to enroll 90 participants across sites in North America and Europe. The objective of the trial is to select the recommended Phase III dose, and to demonstrate the efficacy and safety of the combination in a randomized, controlled setting to support later registrational filings in frontline HR-MDS.

Partnering with Parexel is a key operational milestone as we prepare to advance bexmarilimab into the randomized BEXERA trial,” said Dr. Petri Bono, Chief Medical Officer of Faron. “Their deep experience in hematology and oncology, combined with their global reach will ensure reliable and efficient execution of this trial, which is a critical step in our mission to bring a new treatment option to frontline HR-MDS patients with high unmet needs.”

Dr. Charlotte Moser, Chief Medical Officer of Parexel, added, “We are excited to partner with Faron on this highly significant clinical program. This study represents an important opportunity to create a novel approach for patients with high-risk MDS, where treatment is difficult to dose and alterative treatment options remain limited. Through Parexel Biotech, we bring innovation and agility alongside our global capabilities and deep

hematology expertise to ensure rigorous, high-quality execution, working closely with Faron as they advance bexmarilimab.”

About Bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company’s pipeline is built on its scientific understanding of the regulation of the immune system in cancer.

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register

Faron Pharmaceuticals Ltd | Company announcement | April 14, 2026 at 15:15:00 EEST

Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.
 
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO ACQUIRE ANY SECURITIES. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”) announced on 9 April 2026 results of the share offering (the “Offering“) consisting of 80,158,126 offer shares (the “Offer Shares”). Faron has today registered with the Trade Register maintained by the Patent and Registration Office the remaining 41,944,771 Offer Shares, which were allocated to the primary and secondary subscribers (“Remaining Offer Shares”).

Following the registration of the Remaining Offer Shares, the total number of registered shares in Faron is 203,045,511. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. The Company holds 3,530,573 shares in treasury and therefore, the total number of voting rights in Faron is 199,514,938 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

The Remaining Offer Shares are expected to be recorded on investors’ book-entry accounts on or about 15 April 2026. Applications have been made for the admission to trading of the Remaining Offer Shares on the Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) under the current trading code “FARON”, and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc under the trading code “FARN”. Trading in the Remaining Offer Shares on First North and in the Offer DIs on AIM is expected to commence on First North and AIM on or about 15 April 2026 subject to the admission of the Remaining Offer Shares to trading on First North and AIM.

Faron Pharmaceuticals Ltd

For more information please contact:

IR Partners, Finland
(Media)
Kare Laukkanen		 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Stifel Europe Securities SAS
(Sole Global Coordinator and Bookrunner)
Pierre Kiecolt-Wahl
Vincent Meunier		 pierre.kiecoltwahl@stifel.com
+33 6 30 57 58 82
vincent.meunier@stifel.com
+33 6 30 56 10 06
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Important notice
This announcement is not an offer of securities for sale into the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act“), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into or from the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register the securities in the United States or to make a public offering in the United States. Any sale of the securities in the United States will be made solely to a limited number of “qualified institutional buyers” as defined in Rule 144A in reliance on an exemption from the registration requirements of the Securities Act.

The distribution of this announcement may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for publication, distribution or release, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or the Republic of South Africa or any other jurisdiction in which the distribution, publication or release would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such aforementioned jurisdiction. This announcement is not directed to, and is not intended for distribution to or use by, any person or entity that is a citizen, resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

In any EEA Member State, other than Finland, this release is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the “Prospectus Regulation“).

In the United Kingdom, this announcement is only directed at (a) members of the Company; and (b) “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 (the “POATR“) who are also (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); (ii) persons who fall within Article 49(2)(a) to (d) of the Order; or (iii) other persons to whom it may otherwise be lawfully communicated (all such persons together being “Relevant Persons“). This announcement must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so. Any investment or investment activity to which this announcement relates is only available to Relevant Persons in the United Kingdom and will only be engaged in with such persons.

In the United Kingdom, no prospectus, offering memorandum, offering document or admission document has been or will be made available in connection with the matters contained or referred to in this announcement and no such document is required to be published (in accordance with the POATR or the AIM Rules of the London Stock Exchange). This announcement has not been approved by the Financial Conduct Authority (the “FCA“) or the London Stock Exchange.

No part of this announcement, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The information contained in this release has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company or any of its respective affiliates, advisors or representatives or any other person, shall have no liability whatsoever (in negligence or otherwise) for any loss, however arising from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

The Sole Global Coordinator and Bookrunner is acting exclusively for the Company and no one else in connection with the Offering. It will not regard any other person as their respective client in relation to the Offering. It will not be responsible to anyone other than the Company for providing the duties afforded to its respective clients, nor for giving advice in relation to the Offering or any transaction or arrangement referred to herein.

Caution regarding forward-looking statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Company’s current expectations and assumptions regarding the completion and use of proceeds from the Offering, the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to the Company.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Company believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Back to top